TY  - JOUR
AU  - Holgado, Esther
AU  - Manso, Luis
AU  - Morales, Serafin
AU  - Bermejo, Begoña
AU  - Colomer, Ramon
AU  - Apala, Juan V
AU  - Blanco, Raquel
AU  - Muñoz, Manuel
AU  - Caleiras, Eduardo
AU  - Iranzo, Vega
AU  - Martinez, Mario
AU  - Dominguez, Orlando
AU  - Hornedo, Javier
AU  - Gonzalez-Cortijo, Lucia
AU  - Cortes, Javier
AU  - Gasol Cudos, Ariadna
AU  - Malon, Diego
AU  - Lopez-Alonso, Antonio
AU  - Moreno-Ortíz, María C
AU  - Mañes, Santos
AU  - Quintela Fandino, Miguel Angel
AU  - Mouron, Silvana Andrea
PY  - 2020
DO  - 10.1186/s13058-020-01362-y
UR  - http://hdl.handle.net/20.500.12105/12535
AB  - Preclinical research suggests that the efficacy of immune checkpoint inhibitors in breast cancer can be enhanced by combining them with antiangiogenics, particularly in a sequential fashion. We sought to explore the efficacy and biomarkers of...
LA  - eng
PB  - BioMed Central (BMC)
KW  - THERAPY
KW  - PROLIFERATION
KW  - NORMALIZATION
KW  - PROGRESSION
KW  - EXPRESSION
KW  - 1ST-LINE
KW  - VEGF
TI  - Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial.
TY  - journal article
ER  -